Hyperandrogenism in postmenopausal women: a case report and literature review
-
摘要: 患者女性,71岁。自绝经10年后逐渐出现多毛症、脱发、阴蒂肥大,曾多次查血总睾酮水平升高(1.55~1.79 ng/mL,正常范围为0.08~0.60 ng/mL),硫酸脱氢表雄酮不高,影像学未见肾上腺及卵巢占位,考虑到患者高龄且合并多种代谢并发症,腹腔镜探查手术风险高,试用促性腺激素释放激素类似物曲普瑞林治疗。32周后,患者毛发变软、脱落,监测黄体生成素从31 IU/L降至0.2 IU/L,睾酮回落至正常(0.47 ng/mL),复查影像学未见肿瘤转移或卵巢增大征象。同时,联合生活方式干预以及降脂治疗,可改善患者代谢异常、减轻心理焦虑,提高生活质量。
-
关键词:
- 绝经后高雄激素血症 /
- 促性腺激素释放激素类似物 /
- 多毛症 /
- 代谢异常 /
- 心理健康
Abstract: A 71-year-old female complained of hirsutism, androgenetic alopecia and enlarged clitoris after 10 years of post-menopause. Laboratory examination of total testosterone level was elevated (1.55-1.79 ng/mL, reference range: 0.08-0.60 ng/mL), while dehydroepiandrosterone sulfate was within normal range. No obvious adrenal or ovarian mass was shown on imaging. Laparoscopy exploration was refused owing to advanced age and multiple comorbidities. After the 8-month trial of gonadotropin-releasing hormone analogue triptorelin, improved hirsutism and reduced androgenetic alopecia were observed, with decreased luteinizing hormone levels from 31 to 0.2 IU/L and normalized testosterone levels to 0.47 ng/mL. No signs of tumor metastasis or ovarian enlargement were found on imaging examination. At the same time, the combination of lifestyle intervention and lipid lowering treatment can improve patients ' metabolic abnormalities, alleviate psychological anxiety, and improve their quality of life. -
表 1 中剂量地塞米松抑制试验结果
Table 1. Results of the medium dose dexamethasone suppression test
项目 促肾上腺皮质激素(pg/mL) 睾酮
(ng/mL)17α羟孕酮
(ng/mL)服药前 26.30 1.55 0.59 服药后 < 1.50 1.01 0.27 抑制率(%) 34.8 54.2 -
[1] CUSSEN L, MCDONNELL T, BENNETT G, et al. Approach to androgen excess in women: clinical and biochemical insights[J]. Clin Endocrinol (Oxf), 2022, 97(2): 174-186. doi: 10.1111/cen.14710 [2] SHIFREN J L, DAVIS S R. Androgens in postmenopausal women: a review[J]. Menopause, 2017, 24(8): 970-979. doi: 10.1097/GME.0000000000000903 [3] STANCZYK F Z, CHAIKITTISILPA S, SRIPRASERT I, et al. Circulating androgen levels before and after oophorectomy in premenopausal and postmenopausal women[J]. Climacteric, 2019, 22(2): 169-174. doi: 10.1080/13697137.2018.1535584 [4] KANAKIS G A, TSAMETIS C P, GOULIS D G. Measuring testosterone in women and men [J]. Maturitas, 2019, 125: 41-44. doi: 10.1016/j.maturitas.2019.04.203 [5] SHARMA A, KAPOOR E, SINGH R J, et al. Diagnostic thresholds for androgen-producing tumors or pathologic hyperandrogenism in women by use of total testosterone concentrations measured by liquid chromatography-tandem mass spectrometry[J]. Clin Chem, 2018, 64(11): 1636-1645. doi: 10.1373/clinchem.2018.290825 [6] ELHASSAN Y S, IDKOWIAK J, SMITH K, et al. Causes, patterns, and severity of androgen excess in 1205 consecutively recruited women[J]. J Clin Endocrinol Metab, 2018, 103(3): 1214-1223. doi: 10.1210/jc.2017-02426 [7] 戴好, 卢琳, 邢小平, 等. 中剂量地塞米松雄激素抑制试验在女性高雄激素血症中的诊断价值[J]. 中华医学杂志, 2018, 98(26): 2073-2077. doi: 10.3760/cma.j.issn.0376-2491.2018.26.003DAI H, LU L, XING X P, et al. Efficacy of medium dose dexamethasone androgen suppression test in the diagnosis of female hyperandrogenism[J]. National Medical Journal of China, 2018, 98(26): 2073-2077. doi: 10.3760/cma.j.issn.0376-2491.2018.26.003 [8] ZOU M, CHEN R, WANG Y H, et al. Clinical and ultrasound characteristics of virilizing ovarian tumors in pre- and postmenopausal patients: a single tertiary center experience[J]. Orphanet J Rare Dis, 2021, 16(1): 426. doi: 10.1186/s13023-021-02057-z [9] HICKMAN L C, GOODMAN L, FALCONE T. Value of selective venous catheterization in the diagnosis of hyperandrogenism[J]. Fertil Steril, 2017, 108(6): 1085. doi: 10.1016/j.fertnstert.2017.08.037 [10] MAMOOJEE Y, GANGURI M, TAYLOR N, et al. Clinical case seminar: postmenopausal androgen excess-challenges in diagnostic work-up and management of ovarian thecosis [J]. Clin Endocrinol (Oxf), 2018, 88(1): 13-20. doi: 10.1111/cen.13492 [11] BAHAELDEIN E, BRASSILL M J. Utilisation of gonadotrophin-releasing hormone (GnRH) analogue to differentiate ovarian from adrenal hyperandrogenism in postmenopausal women[J]. Endocrinol Diabetes Metab Case Rep, 2018, 2018: 18-0084. DOI: 10.1530/EDM-18-0084. [12] HIRSCHBERG A L. Approach to investigation of hyperandrogenism in a postmenopausal woman[J]. J Clin Endocrinol Metab, 2022: dgac673. DOI: 10.1210/clinem/dgac673. [13] 王曦, 许建萍, 刘兆祥, 等. GnRH类似物治疗绝经后促性腺激素依赖性高雄激素血症持续缓解一例并文献复习[J]. 中华内分泌代谢杂志, 2018, 34(1): 53-56.WANG X, XU J P, LIU Z X, et al. Effective GnRH analogue treatment and persistent remission of postmenopausal gonadotropin dependent hyperandrogenism: one case report and literature review[J]. Chinese Journal of Endocrinology and Metabolism, 2018, 34(1): 53-56. [14] 万惠卿, 蔡玉群, 李薇, 等. 女性血清睾酮水平及年龄与代谢综合征的关系[J]. 中华全科医学, 2016, 14(2): 251-253. doi: 10.16766/j.cnki.issn.1674-4152.2016.02.030WAN H Q, CAI Y Q, LI W, et al. Correlation between serum testosterone and age with metabolic syndrome in women[J]. Chinese Journal of General Practice, 2016, 14(2): 251-253. doi: 10.16766/j.cnki.issn.1674-4152.2016.02.030 [15] ZAMAN A, ROTHMAN M S. Postmenopausal hyperandrogenism: evaluation and treatment strategies[J]. Endocrinol Metab Clin North Am, 2022, 50(1): 97-111.